View Older Stories View More Recent Stories
-
Wolfe: 'We're observing some reports of GLP-1 users refreshing their wardrobes as weight loss progresses'
-
Pfizer (PFE) PT Raised to $36 at Guggenheim
-
Pfizer advises shareholders to reject Tutanota mini-tender offer
-
Pfizer's TALZENNA combination shows progress against prostate cancer
-
Morgan Stanley on Pfizer (PFE): Atirmo Ph2 data an 'incremental positive'
-
Stocks expected to have increasing option volume: LMND MRNA PFE BNTX NVAX AZN BMY LLY GSK JNJ MRK NVS MRK SNY
-
US Judge blocks Trump Admin cuts to number of routinely recommended vaccines for children - Reuters
-
BMO Capital Reiterates Outperform Rating on Pfizer (PFE) following Ph2 data
-
FDA: 'The agency today is withdrawing final guidance titled “Scientific Considerations in Demonstrating Biosimilarity to a Reference Product'
-
Argus Upgrades Pfizer (PFE) to Buy
-
PADCEV plus Keytruda reduces bladder cancer recurrence risk by 47%
-
RBC Capital Starts Pfizer (PFE) at Underperform
-
FDA approves Pfizer's BRAFTOVI for colorectal cancer treatment
-
Barclays Starts Pfizer (PFE) at Underweight
-
Pfizer's BRAFTOVI shows improved survival in colorectal cancer trial
-
Bernstein Reiterates Market Perform Rating on Pfizer (PFE)
-
Pfizer (PFE) PT Lowered to $33 at Freedom Capital Markets
-
Pfizer (PFE) Launches Cost Savings Program on TrumpRx
-
Pfizer (PFE) Tops Q4 EPS by 8c, Beats on Revenue; Offers FY26 Guidance
-
Pfizer obesity drug shows 12.3% weight loss in phase 2b trial
-
Pfizer earnings preview Q4: softer print expected, drug pipeline in focus
-
Pfizer (PFE) call put ratio 2.2 calls to 1 put into quarter results
-
Pfizer (PFE) call put ratio 3.3 calls to 1 put into quarter results
-
Pfizer (PFE) call put ratio 2.5 calls to 1 put into quarter results
-
Eli Lilly, Pfizer, AbbVie drugs targeted in third Medicare price talks
-
Goldman Sachs Previews Pfizer (PFE) Earnings
-
Bernstein Reiterates Market Perform Rating on Pfizer (PFE)
-
Shionogi Invests $2.1 bln To Raise Stake in Viiv Healthcare - Bloomberg
-
Pfizer (PFE) CEO: to launch next-gen obesity assets acquired through Metsera buyout in 2028 - JPM Conference
-
Pfizer's BRAFTOVI shows improved response rates in colorectal cancer trial
-
Pfizer (PFE) call put ratio 1.2 calls to 1 put into the annual J.P. Morgan Healthcare Conference
-
UBS Assumes Pfizer (PFE) at Neutral
-
FDA revokes emergency use authorizations (EMAs) issued to Pfizer for lucira by Pfizer Covid-19 & flu test
-
Drugmakers Raise Us Prices On 350 Medicines Despite Pressure From Trump - Reuters
-
TD Cowen Reiterates Hold Rating on Pfizer (PFE)
-
Pfizer: does not anticipate any impact to safety for patients treated with approved marstacimab
-
Patient Dies After Taking Pfizer’s Drug for Blood Disorder
-
Trump to announce prescription drug price agreements
-
BMO Capital on Pfizer (PFE): 'Conservative Guide Sets the Stage for 2026 Post Metsera'
-
Bernstein Reiterates Market Perform Rating on Pfizer (PFE)
-
PADCEV-Keytruda combo shows survival benefit in bladder cancer trial
-
Guggenheim Reiterates Buy Rating on Pfizer (PFE)
-
Pfizer (PFE) PT Lowered to $24 at Wolfe Research
-
Pfizer (PFE) PT Lowered to $27 at BofA Securities
-
Pfizer provides 2026 financial guidance with lower revenue and earnings outlook
-
Adaptive Biotechnologies signs two TCR licensing deals with Pfizer
-
Pfizer (PFE) Declares $0.43 Quarterly Dividend; 6.6% Yield
-
FDA may add black box warning to Covid-19 vaccines, CNN says
-
BMO Capital on Pfizer (PFE): 'Results are positive for tucatinib commercial expansion'
-
Pfizer's TUKYSA extends progression-free survival in breast cancer trial
